Atara Biotherapeutics, Inc. 8-K

What Happened
Atara Biotherapeutics, Inc. filed an 8-K on March 3, 2026 to announce a press release stating that Pierre Fabre Pharmaceuticals, Inc. has submitted a request for a Type A meeting with the U.S. Food and Drug Administration (FDA). The meeting request is to discuss Pierre Fabre’s plan to address issues raised by the FDA in the Complete Response Letter (CRL) for the EBVALLO™ Biologics License Application (BLA) issued on January 9, 2026. The press release is included as Exhibit 99.1 to the filing.

Key Details

• Press release dated March 3, 2026 announcing the regulatory update.
• Pierre Fabre Pharmaceuticals submitted a request for a Type A meeting with the FDA.
• The meeting seeks to address deficiencies noted in the CRL for the EBVALLO™ (tabelecleucel) BLA issued January 9, 2026.
• The press release is filed as Exhibit 99.1 and incorporated by reference in the 8-K.

Why It Matters
This filing confirms that a formal regulatory step (a Type A meeting request) has been initiated to resolve the FDA’s concerns about the EBVALLO BLA for tabelecleucel. For investors, it signals ongoing regulatory review and that the sponsor is engaging the FDA to try to address the CRL items; investors should monitor for the meeting schedule, outcomes, and any subsequent filings or FDA communications for concrete updates on the approval timeline.